This is a Study to Evaluate the Safety and Tolerability of ABL503, and to Determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of ABL503 in Subjects with Any Progressive Locally Advanced or Metastatic Solid Tumors
This is a Study to Evaluate the Safety and Tolerability of ABL503, and to Determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of ABL503 in Subjects with Any Progressive Locally Advanced or Metastatic Solid Tumors
Recruiting · NCT04762641 · Registry updated 2025-02-06Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| This is a Study to Evaluate the Safety and Tolerability of ABL503, and to Determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of ABL503 in Subjects with Any Progressive Locally Advanced or Metastatic Solid Tumors | Advanced Solid Tumor | Recruiting | Phase 1 | 2025-02-06 | NCT04762641 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| ABL Bio, Inc. | 3 |
8 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Asan Medical Center | Seoul | South Korea | 338 |
| City of Hope | Duarte | United States | 238 |
| NEXT Oncology | San Antonio | United States | 70 |
| Sarah Cannon Research Institute at HealthOne | Denver | United States | 34 |
| Seoul National University Hospital | Seoul | South Korea | 393 |
| Severance Hospital | Seoul | South Korea | 81 |
| UCLA | Santa Monica | United States | 14 |
| USC | Los Angeles | United States | 3 |